Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.78 AUD -3.39% Market Closed
Market Cap: 8.4B AUD

Relative Value

The Relative Value of one TLX stock under the Base Case scenario is 30.81 AUD. Compared to the current market price of 24.78 AUD, Telix Pharmaceuticals Ltd is Undervalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TLX Relative Value
Base Case
30.81 AUD
Undervaluation 20%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
39
Median 3Y
11.3
Median 5Y
20.7
Industry
7.2
Forward
6.4
vs History
19
vs Industry
1
Median 3Y
-12.2
Median 5Y
-18.4
Industry
23.2
Forward
45.4
vs History
30
vs Industry
1
Median 3Y
144.2
Median 5Y
-12.4
Industry
19.3
vs History
46
vs Industry
10
Median 3Y
14.6
Median 5Y
-11.9
Industry
22.5
vs History
76
vs Industry
5
Median 3Y
22
Median 5Y
21.1
Industry
2.7
vs History
71
vs Industry
33
Median 3Y
11.1
Median 5Y
20
Industry
7.5
Forward
6.3
vs History
71
vs Industry
26
Median 3Y
17.9
Median 5Y
33.7
Industry
9.4
vs History
19
vs Industry
1
Median 3Y
-11.5
Median 5Y
-18.1
Industry
4.6
Forward
40.8
vs History
19
vs Industry
1
Median 3Y
-11.5
Median 5Y
-18.1
Industry
4.5
Forward
35.5
vs History
30
vs Industry
1
Median 3Y
142.2
Median 5Y
-11.5
Industry
4.9
vs History
vs Industry
0
Median 3Y
-13.4
Median 5Y
-17.1
Industry
3.7
vs History
80
vs Industry
16
Median 3Y
16.4
Median 5Y
16.1
Industry
4.9

Multiples Across Competitors

TLX Competitors Multiples
Telix Pharmaceuticals Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Telix Pharmaceuticals Ltd
ASX:TLX
8.3B AUD 10.6 166.2 101.9 101.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 202 723.3 -162 560.5 -197 400.3 -195 147.7
US
Abbvie Inc
NYSE:ABBV
337.5B USD 5.9 81.2 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
136.9B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 10.5 -118.3 25.2 26.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 059.8 -525.6 -572.3 -557.1
AU
CSL Ltd
ASX:CSL
115.7B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
57.3B USD 4.1 12.7 11.3 12.7
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.1B USD 17.1 -148.8 -666.4 -333.9
P/S Multiple
Revenue Growth P/S to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/S: 3 109 533.2
10.6
35%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 202 723.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1.1
US
E
Epizyme Inc
F:EPE
2 059.8
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.1
4%
1
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/E: 56.2
166.2
97%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 560.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.2
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBITDA: 27.9
101.9
79%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 400.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.3 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -666.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBIT: 31.8
101.9
88%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 147.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -333.9 N/A N/A